Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Alterity Therapeutics ( (AU:ATH) ) has shared an announcement.
Alterity Therapeutics has appointed neurologist and movement disorder expert Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor, while he maintains his professorship at Vanderbilt University Medical Center. Claassen, an internationally recognized authority on neurodegenerative diseases with extensive clinical trial and translational research experience, has been instrumental in Alterity’s ATH434 program and previously served as coordinating investigator for its Phase 2 study in Multiple System Atrophy.
The appointment comes as Alterity readies ATH434 for a Phase 3 pivotal trial in Multiple System Atrophy following promising Phase 2 results that showed clinically meaningful slowing of disease progression. By adding Claassen’s deep expertise in movement disorders, biomarker discovery, and global trial leadership, the company aims to strengthen its clinical strategy, accelerate development of ATH434, and expand its pipeline of novel therapies for neurodegenerative conditions, potentially enhancing its position in the niche MSA treatment landscape.
The most recent analyst rating on (AU:ATH) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
More about Alterity Therapeutics
Alterity Therapeutics is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, particularly Multiple System Atrophy and related Parkinsonian disorders. Headquartered in Melbourne and San Francisco, the company’s lead candidate ATH434 has shown clinically meaningful efficacy in Phase 2 trials, and Alterity is preparing a pivotal Phase 3 study while advancing a broader discovery platform of patentable neurological compounds.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$87M
For a thorough assessment of ATH stock, go to TipRanks’ Stock Analysis page.